Kılıç Soylar Öznur, Kılınç Oğuz, Ellidokuz Hülya
Department of Chest Diseases, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey.
Tuberk Toraks. 2015 Sep;63(3):165-9.
Objective of this study is to compare the difference between the length of hospitalisation, cost of treatment and treatment outcome of patients diagnosed with community acquired pneumonia and treated with beta-lactam-macrolide combination or fluoroquinolone monotherapy, according to 2009 Turkish Thoracic Society (TTS) Guide of Diagnosis and Treatment of Community Acquired Pneumonia in Adults (TTSCAPG).
Patients diagnosed with community-acquired pneumonia (CAP) between November 2010 and November 2011 in our hospital were included. The data was entered into TTS pneumonia database. Cases were examined for their accordance with TTSCAPG. Clinical outcomes of the patients treated with beta-lactam-macrolide combination or fluoroquinolone, were compared.
One hundred and fifty six patients diagnosed with community-acquired pneumonia were included. 67.3% of the patients were treated according to the guideline. Of the patients treated in accordance with the guideline, 86.7% were treated with beta-lactam-macrolide combination and 13.3% with fluoroquinolone. Of the patients treated with combination therapy, the treatment was effective in 77.7%, ineffective in 11.8% and 10.6% resulted in death; where as the patients treated with fluoroquinolone, the treatment was effective in 84.7%, ineffective in 15.4%, none of them resulted in death.
Cases diagnosed with community-acquired pneumonia and treated according to the TTSCAPG guideline were evaluated for effectiveness of combination therapy versus fluoroquinolone; no statistically difference in terms of age, diseases, length of stay, treatment outcomes, cost of treatment could be established. There was only a numerical difference between mortality outcomes of the two antibiotherapy groups compared, however the statistical difference was not significant.
本研究的目的是根据2009年土耳其胸科学会（TTS）成人社区获得性肺炎诊断和治疗指南（TTSCAPG），比较诊断为社区获得性肺炎并接受β-内酰胺类-大环内酯类联合治疗或氟喹诺酮单药治疗的患者在住院时间、治疗费用和治疗结果方面的差异。
纳入2010年11月至2011年11月在我院诊断为社区获得性肺炎（CAP）的患者。数据录入TTS肺炎数据库。检查病例是否符合TTSCAPG。比较接受β-内酰胺类-大环内酯类联合治疗或氟喹诺酮治疗的患者的临床结果。
纳入156例诊断为社区获得性肺炎的患者。67.3%的患者按照指南进行治疗。在按照指南治疗的患者中，86.7%接受β-内酰胺类-大环内酯类联合治疗，13.3%接受氟喹诺酮治疗。在接受联合治疗的患者中，治疗有效率为77.7%，无效率为11.8%，10.6%导致死亡；而接受氟喹诺酮治疗的患者，治疗有效率为84.7%，无效率为15.4%，无一例死亡。
对诊断为社区获得性肺炎并按照TTSCAPG指南进行治疗的病例，评估联合治疗与氟喹诺酮治疗的有效性；在年龄、疾病、住院时间、治疗结果、治疗费用方面未发现统计学差异。比较的两个抗菌治疗组的死亡率结果仅存在数值差异，但统计学差异不显著。
